Although lower TGFβR2 mRNA levels in AML patients may be due to escaping from inhibition of TGFβ1 [32], patients with relatively higher TGFβR2 levels acquired poorer OS that may attribute to stronger invasiveness and drug resistance ability. Here, TGFBR2 is linked to acute myeloid leukemia.